Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 23, Issue 10, 2010, Pages 1139-1142

  Rebarber, Andrei ^a   Fox, Nathan S ^a   Klauser, Chad K ^a   Istwan, Niki B ^b   Rhea, Debbie J ^b   Stanziano, Gary J ^b   Saltzman, Daniel H ^a  

^a Maternal Fetal Medicine Associates   (United States)

^b Women's and Children's Health ^*  (United States)

Author keywords

17 hydroxyprogesterone caproate; preterm birth prevention; progesterone

Indexed keywords

HYDROXYPROGESTERONE CAPROATE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; ETHNICITY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT EDUCATION; PATIENT SATISFACTION; PREMATURE LABOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HOME CARE SERVICES; HUMANS; HYDROXYPROGESTERONES; INJECTIONS, INTRAMUSCULAR; OBSTETRIC LABOR, PREMATURE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PREGNANCY; PREMATURE BIRTH; PRENATAL CARE; PROGESTINS; YOUNG ADULT;

EID: 77956561440     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767051003615418     Document Type: Article

References (13)

1. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, Mathews TJ. Births: final data for 2006. National vital statistics reports. Vol 57. No. 7. Hyattsville, MD: National Center for Health Statistics; 2009.
2. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989;96:265-274.
3. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW. Prevention of recurrent preterm delivery by 17-ahydroxyprogesterone caproate. N Eng J Med 2003;348: 2379-2385.
4. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273-279. (Pubitemid 40229441)
5. American College of Obstetricians and Gynecologists. ACOG Committee Opinion, Number 419. Use of progesterone to reduce preterm birth. Obstet Gynecol 2008;112 963-965.
6. Meis PJ. 17 Hydroxyprogesterone for the prevention of preterm delivery. Obstet Gynecol 2005;105;1128-1135.
7. da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebocontrolled double-blind study. Am J Obstet Gynecol 2003; 188:419-424.
8. Johnstone EE, Franklin RR. Assay of progestins for fetal virilizing properties using the mouse. Obstet Gynecol 1964; 23:359-362.
9. Courtney KD, Valerio DA. Teratology in the Macaca mulatta.Teratology 1968;1:163-72.
10. Carbone JP, Brent RL. Genital and nongenital teratogenesis of prenatal progesterone therapy: the effects of 17a-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6L mouse. Am J Obstet Gynecol 1993;169:1292-1298.
11. Miller RE, Nelson GW, Johnson CK. Evaluation of teratogenic potential of Delalutin, (17 a-hydroxyprogesterone caproate) in mice. Teratology 1983;28:201-208.
12. Ness A, Dias T, Damus K, Burd I, Berghella V. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol 2006;195:1174-1179.
13. Papiernik-Berkhauer E. Etude en double aveugle dun medicament prevenant la survenue prematuree de laccouchement chez les femmes a risque eleve daccouchement premature. Edition Schering Serie IV 1970;3:65-68. ik.